Nilotinib Teva

Nilotinib, the active ingredient in Nilotinib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in the chronic phase.

GNH USA supplies Nilotinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy used in the treatment of BCR‑ABL positive leukemias.

Chronic Myeloid Leukemia (CML) in chronic phase: reduces leukemic cell proliferation and improves survival. Philadelphia‑positive CML: selectively blocks the BCR‑ABL kinase driving disease activity. CML after imatinib resistance: provides an alternative oral tyrosine‑kinase inhibition strategy.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may require fluid replacement. - Rash: skin irritation or erythema. - Fatigue: persistent feeling of tiredness.

Serious or Rare Side Effects: - Cardiovascular events: arterial occlusive disease or ischemia. - Pancreatitis: inflammation of the pancreas with abdominal pain. - QT interval prolongation: heart rhythm disturbance that can lead to arrhythmia. - Severe liver injury: marked elevation of liver enzymes and possible hepatitis.

Before initiating therapy, clinicians should assess several safety parameters. - Cardiac monitoring: evaluate baseline ECG and cardiovascular risk factors. - Liver function: check hepatic enzymes and monitor for signs of hepatitis. - Blood glucose: monitor for hyperglycemia, especially in diabetic patients. - Hypersensitivity: discontinue if severe allergic reactions occur. - Renal impairment: adjust dosing and monitor renal function as needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nilotinib can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure. - Antacids containing aluminum or magnesium: reduce absorption of nilotinib. - St. John's wort (CYP3A4 inducer): can markedly lower nilotinib levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Antidiabetic agents (e.g., insulin, sulfonylureas): watch for changes in blood glucose.